[go: up one dir, main page]

WO2009063459A3 - Synthetic peptide copolymers for treatment of neurodevelopmental disorders - Google Patents

Synthetic peptide copolymers for treatment of neurodevelopmental disorders Download PDF

Info

Publication number
WO2009063459A3
WO2009063459A3 PCT/IL2008/001489 IL2008001489W WO2009063459A3 WO 2009063459 A3 WO2009063459 A3 WO 2009063459A3 IL 2008001489 W IL2008001489 W IL 2008001489W WO 2009063459 A3 WO2009063459 A3 WO 2009063459A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
synthetic peptide
neurodevelopmental disorders
peptide copolymers
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/001489
Other languages
French (fr)
Other versions
WO2009063459A2 (en
Inventor
Bruria Ben-Zeev Ghidoni
Ruth Arnon
Rina Aharoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tel HaShomer Medical Research Infrastructure and Services Ltd
Yeda Research and Development Co Ltd
Original Assignee
Tel HaShomer Medical Research Infrastructure and Services Ltd
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel HaShomer Medical Research Infrastructure and Services Ltd, Yeda Research and Development Co Ltd filed Critical Tel HaShomer Medical Research Infrastructure and Services Ltd
Publication of WO2009063459A2 publication Critical patent/WO2009063459A2/en
Publication of WO2009063459A3 publication Critical patent/WO2009063459A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, are useful for treatment of neurodevelopmental disorders, particularly Rett syndrome.
PCT/IL2008/001489 2007-11-13 2008-11-13 Synthetic peptide copolymers for treatment of neurodevelopmental disorders Ceased WO2009063459A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99632607P 2007-11-13 2007-11-13
US60/996,326 2007-11-13

Publications (2)

Publication Number Publication Date
WO2009063459A2 WO2009063459A2 (en) 2009-05-22
WO2009063459A3 true WO2009063459A3 (en) 2010-01-28

Family

ID=40639261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/001489 Ceased WO2009063459A2 (en) 2007-11-13 2008-11-13 Synthetic peptide copolymers for treatment of neurodevelopmental disorders

Country Status (1)

Country Link
WO (1) WO2009063459A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (en) 2011-04-21 2017-02-16 Mapi Pharma Limited Random Pentapolymer for the treatment of autoimmune diseases
WO2015002527A1 (en) * 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
CN105707626A (en) * 2016-03-02 2016-06-29 广东蓝水星食品有限公司 Lactic acid bacterium fermented fruit and vegetable smoothie and preparation method thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (en) 2016-08-31 2023-07-31 Mapi Pharma Ltd DEPOT SYSTEMS INCLUDING GLATIRAMER ACETATE
JP7602322B2 (en) 2017-03-26 2024-12-18 マピ ファーマ リミテッド Glatiramer depot system for treating progressive multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005250A1 (en) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005250A1 (en) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG QIANG ET AL: "The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression", NEURON, CELL PRESS, US, vol. 49, no. 3, 2 February 2006 (2006-02-02), pages 341 - 348, XP002510445, ISSN: 0896-6273 *
MAN CHEN ET AL: "GLATIRAMER ACETATE-REACTIVE T CELLS PRODUCE BRAIN-DERIVED NEUROTROPHIC FACTOR", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 215, 1 January 2003 (2003-01-01), pages 37 - 44, XP008076627, ISSN: 0022-510X *
NEUL JEFFREY L ET AL: "Rett syndrome: A prototypical neurodevelopmental disorder.", NEUROSCIENTIST, vol. 10, no. 2, April 2004 (2004-04-01), pages 118 - 128, XP009126127, ISSN: 1073-8584 *

Also Published As

Publication number Publication date
WO2009063459A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
WO2009063459A3 (en) Synthetic peptide copolymers for treatment of neurodevelopmental disorders
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2009017837A3 (en) Sublingual fentanyl spray
WO2007087431A3 (en) Sublingual fentanyl spray
WO2008019357A3 (en) Indole compounds
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
WO2006074391A3 (en) Biodegradable coating compositions comprising blends
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2008021410A3 (en) Highly pure pemetrexed diacid and processes for the preparation thereof
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2008121767A3 (en) Stitched polypeptides
IL197923A (en) Synthetic peptide amides, pharmaceutical compositions comprising the same and uses thereof
WO2009062044A3 (en) Processes for the preparation of prasugrel, and its salts and polymorphs
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2007117431A3 (en) Use of rasagiline for the treatment of restless legs syndrome
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
IL178018A0 (en) Drug delivery system based on polyethylene vinylacetate copolymers
WO2009032749A3 (en) Salicylanilide modified peptides for use as oral therapeutics
WO2008120080A3 (en) An improved process for the synthesis of solifenacin
WO2006010057A3 (en) Therapeutic peptides
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
WO2009023761A3 (en) Pharmaceutical compositions comprising ropinirole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08849668

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08849668

Country of ref document: EP

Kind code of ref document: A2